Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone857-449-2244
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees13
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Karuna Therapeutics (NASDAQ:KRTX) Frequently Asked Questions
What is Karuna Therapeutics' stock symbol?
Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."
How were Karuna Therapeutics' earnings last quarter?
Karuna Therapeutics (NASDAQ:KRTX) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($146.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.19) by $144.83. View Karuna Therapeutics' Earnings History.
When is Karuna Therapeutics' next earnings date?
What price target have analysts set for KRTX?
4 analysts have issued twelve-month target prices for Karuna Therapeutics' stock. Their forecasts range from $28.00 to $38.00. On average, they expect Karuna Therapeutics' stock price to reach $32.25 in the next twelve months. This suggests a possible upside of 100.9% from the stock's current price. View Analyst Price Targets for Karuna Therapeutics.
What is the consensus analysts' recommendation for Karuna Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karuna Therapeutics.
Has Karuna Therapeutics been receiving favorable news coverage?
Media coverage about KRTX stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Karuna Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Karuna Therapeutics.
Who are some of Karuna Therapeutics' key competitors?
Some companies that are related to Karuna Therapeutics include Aimmune Therapeutics (AIMT), Corcept Therapeutics (CORT), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), G1 Therapeutics (GTHX), Turning Point Therapeutics (TPTX), Theravance Biopharma (TBPH), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Gossamer Bio (GOSS), BELLUS Health (BLUSF), AnaptysBio (ANAB) and Ra Pharmaceuticals (RARX).
What other stocks do shareholders of Karuna Therapeutics own?
Who are Karuna Therapeutics' key executives?
Karuna Therapeutics' management team includes the folowing people:
- Dr. Steven M. Paul M.D., Chairman & CEO (Age 68)
- Dr. Andrew Craig Miller, Founder, COO & Director
- Dr. Edmund P. Harrigan M.D., Director (Age 66)
- Dr. Richard Kavoussi, Chief Medical Officer
- Dr. Alan Breier, Chief Clinical Advisor
When did Karuna Therapeutics IPO?
(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When does the company's lock-up period expire?
Karuna Therapeutics' lock-up period expires on Wednesday, December 25th. Karuna Therapeutics had issued 5,578,124 shares in its initial public offering on June 28th. The total size of the offering was $89,249,984 based on an initial share price of $16.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Who are Karuna Therapeutics' major shareholders?
Karuna Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sofinnova Investments Inc. (7.39%), Price T Rowe Associates Inc. MD (1.94%), Rock Springs Capital Management LP (1.77%), Vivo Capital LLC (1.39%), Citadel Advisors LLC (0.54%) and Monashee Investment Management LLC (0.49%). Company insiders that own Karuna Therapeutics stock include Arch Venture Partners Ix, Llc, James Healy and Steven M Paul. View Institutional Ownership Trends for Karuna Therapeutics.
Which major investors are buying Karuna Therapeutics stock?
KRTX stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Price T Rowe Associates Inc. MD, Rock Springs Capital Management LP, Vivo Capital LLC, Citadel Advisors LLC, Monashee Investment Management LLC, Pentwater Capital Management LP and Vanguard Group Inc.. Company insiders that have bought Karuna Therapeutics stock in the last two years include Arch Venture Partners Ix, Llc, James Healy and Steven M Paul. View Insider Buying and Selling for Karuna Therapeutics.
How do I buy shares of Karuna Therapeutics?
Shares of KRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Karuna Therapeutics' stock price today?
One share of KRTX stock can currently be purchased for approximately $16.05.
How big of a company is Karuna Therapeutics?
What is Karuna Therapeutics' official website?
How can I contact Karuna Therapeutics?
Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company can be reached via phone at 857-449-2244 or via email at [email protected]
MarketBeat Community Rating for Karuna Therapeutics (NASDAQ KRTX)
MarketBeat's community ratings are surveys of what our community members think about Karuna Therapeutics and other stocks. Vote "Outperform" if you believe KRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
